Cefepime Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Cefepime Shortage in 2026

The Cefepime shortage continues to affect hospitals and healthcare systems across the United States in 2026. As a provider, you're likely already managing the downstream effects — altered empiric regimens, stewardship committee discussions, and concerned patients wondering why their prescribed antibiotic isn't available.

This briefing provides a concise overview of the current shortage landscape, clinical implications, alternative strategies, and tools you can use to help your patients access treatment. For the patient-facing version, see our patient shortage update.

Shortage Timeline and Current Status

Cefepime injection has been on the ASHP Drug Shortages list intermittently since the early 2010s. The current shortage cycle began around 2022-2023 and has persisted through 2025-2026. Key timeline points:

• 2014-2015: First major nationwide shortage driven by manufacturing quality issues
• 2017-2018: Recurrent shortages as manufacturer consolidation reduced the supply base
• 2022-2023: Current shortage cycle begins, driven by manufacturing delays at B. Braun and supply disruptions from other manufacturers
• 2024-2025: Shortage continues with intermittent partial resupply; some formulations more affected than others
• 2026 (current): B. Braun Cefepime remains on shortage due to manufacturing delays. Apotex, Baxter, and Hospira (Pfizer) report intermittent availability

The shortage affects 500 mg, 1 g, and 2 g vials as well as premixed frozen IV solutions. Availability varies significantly by region, distributor, and institutional purchasing agreements.

Prescribing Implications

The Cefepime shortage has several clinical and prescribing implications that providers should consider:

Empiric Regimen Adjustments

Many hospital antimicrobial stewardship programs have issued guidelines for Cefepime-sparing regimens during the shortage. Common adjustments include:

• Febrile neutropenia: Substitution with Piperacillin-Tazobactam 4.5 g IV q6h or Meropenem 1 g IV q8h per IDSA guidelines, which list both as acceptable first-line alternatives
• Hospital-acquired pneumonia: Ceftazidime 2 g IV q8h or Piperacillin-Tazobactam 4.5 g IV q6h for Pseudomonal coverage
• Complicated UTI/pyelonephritis: Ceftazidime 1-2 g IV q8h or, for less severe cases, step-down to oral Fluoroquinolones (Ciprofloxacin, Levofloxacin) if susceptibilities allow
• Intra-abdominal infections: Piperacillin-Tazobactam provides equivalent or superior anaerobic coverage and serves as a direct substitute

Neurotoxicity Considerations

A relevant clinical note: the FDA issued a Drug Safety Communication regarding Cefepime-associated neurotoxicity (encephalopathy, myoclonus, seizures, nonconvulsive status epilepticus), primarily in patients ≥50 years with renal dysfunction who did not receive appropriate dose adjustments. When restarting Cefepime after a period of unavailability, ensure renal dosing protocols are current. For detailed safety information, see our article on Cefepime side effects.

Extended Infusion Dosing

Extended infusion protocols (infusing Cefepime 2 g over 3-4 hours rather than the standard 30 minutes) have been studied for improved pharmacokinetic-pharmacodynamic target attainment. During shortages, some institutions have adopted extended infusion as a dual strategy: improved efficacy for Pseudomonas coverage and potentially reduced total drug utilization through optimized dosing.

Current Availability Picture

As of early 2026, the availability landscape includes:

• B. Braun: Cefepime on shortage — manufacturing delays, no confirmed resupply date
• Apotex: Intermittent availability; allocating limited supply through distributors
• Baxter: Premixed frozen solutions have been variably affected; some formulations available
• Hospira (Pfizer): Some vial sizes available; supply inconsistent by region

Institutional buyers with group purchasing organization (GPO) contracts may have preferential access, but even large health systems report intermittent stockouts. Independent hospitals and smaller systems are often more severely affected.

Cost and Access Considerations

Cefepime remains available only as a generic; the original brand Maxipime is no longer actively marketed. Current pricing:

• Hospital acquisition cost: Varies by GPO contract, but generic vials typically range from $5-$25 per unit for institutional buyers
• Outpatient/home infusion: Cash price approximately $363 for 9 × 2 g vials; discount cards bring this to approximately $93
• Patient out-of-pocket: Variable based on insurance; home infusion patients may face significant costs depending on coverage

During shortages, gray-market pricing can inflate costs dramatically. The FDA recommends sourcing only through verified distributors.

Tools and Resources for Providers

Several tools can help you and your patients navigate the shortage:

• Medfinder for Providers: Track real-time Cefepime availability across pharmacies and facilities. Share with patients who need to locate supply for home infusion
• ASHP Drug Shortage Resource Center: Provides manufacturer-level updates, estimated resupply dates, and clinical management strategies
• FDA Drug Shortage Database: Official shortage information and FDA actions to address supply gaps
• Institutional antimicrobial stewardship programs: Your hospital's ASP team likely has shortage-specific protocols — connect with them if you haven't already

For a practical guide on helping patients find Cefepime, see our provider's guide to helping patients find Cefepime in stock.

Looking Ahead

Several developments may improve the Cefepime supply situation:

• FDA expedited generic reviews: The FDA has prioritized review of new generic applications for drugs on the shortage list, including Cefepime injection
• Cefepime-Enmetazobactam (Exblifep): This FDA-approved combination product adds a treatment option for complicated UTIs and may reduce demand for standard Cefepime in some clinical scenarios
• Manufacturer capacity expansion: Several manufacturers have announced capacity investments for sterile injectable production, though timelines remain uncertain
• Policy initiatives: The GAO's 2025 report on drug shortages recommended that HHS implement better coordination mechanisms, which may lead to structural improvements

Final Thoughts

The Cefepime shortage requires proactive management at both the institutional and individual patient level. Stay connected with your antimicrobial stewardship team, monitor ASHP and FDA updates, and use tools like Medfinder for Providers to help patients locate medication.

When Cefepime is unavailable, evidence supports several alternatives including Ceftazidime, Piperacillin-Tazobactam, and Meropenem — each with trade-offs that should be weighed against the clinical context. For a comprehensive look at alternatives, see our alternatives guide.

For guidance on helping patients manage costs, review our provider's guide to helping patients save money on Cefepime.